FDA grants EBTATE investigational new drug status

By AuntMinnie.com staff writers

March 3, 2021 -- Biotechnology developer Molecular Targeting Technologies has received investigational new drug approval from U.S. Food and Drug Administration (FDA) to study EBTATE use in patients with neuroendocrine tumors.

EBTATE is used for targeted radionuclide therapy and is used to append Evans blue (EB) to a targeting radiopharmaceutical. EB binds reversibly to serum albumin, enhancing radiotherapeutic time window with longer circulation half-life and increasing tumor uptake to improve outcomes.


Copyright © 2021 AuntMinnie.com
 

To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking
account: